Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours

被引:22
|
作者
Ricci, Claudio [1 ]
Casadei, Riccardo [1 ]
Taffurelli, Giovanni [1 ]
Campana, Davide [1 ]
Ambrosini, Valentina [2 ]
Pagano, Nico [1 ]
Santini, Donatella [2 ]
De Giorgio, Roberto [1 ]
Ingaldi, Carlo [1 ]
Tomassetti, Paola [1 ]
Zani, Elia [1 ]
Minni, Francesco [1 ]
机构
[1] Univ Bologna, Alma Mater Studiorum, Dept Internal Med & Surg DIMEC, S Orsola Malpighi Hosp, I-40126 Bologna, Italy
[2] Univ Bologna, Alma Mater Studiorum, Dept Haematol & Oncol DIMES, S Orsola Malpighi Hosp, I-40126 Bologna, Italy
关键词
Ki-67; Pancreatic endocrine neoplasm; Surgery; Classification; World Health Organization; Decision curve analysis; LYMPH-NODE RATIO; GRADING SYSTEM; ENDOCRINE TUMORS; GUIDELINES; RECURRENCE; KI67;
D O I
10.1016/j.pan.2016.02.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Backgound: In 2010, the World Health Organization (WHO) modified the classification for pancreatic neuroendocrine tumours (NETS). Recently, some modifications were proposed to improve its prognostic value. The aim of this study was to test the prognostic value of both the original and the modified 2010 WHO grading systems. Methods: One hundred and twenty consecutive patients surgically resected for well-differentiated NETs were evaluated in multivariate Cox regression models. Age, sex, hormonal status, size, lymph node ratio, stage, margin status and grading were evaluated in order to predict disease-free survival (DFS). Four models were evaluated: model 1: grading according to the 2010 WHO; model 2: modified grading with cut-off at 5% of the Ki-67 index; model 3: modified grading in which the G2 category was divided into two subgroups (2-5% and 5-20%) and model 4: the Ki-67 index as a continuous variable. Decision curve analysis (DCA) was carried out to evaluate the clinical utility of the various cut-offs. Results: All the grading systems remained independent factors in predicting DFS. Model 2 (c index = 0.814 and P = 0.012) and model 3 (c index = 0.865 and P = 0.015) showed higher predictive powers with respect to model 1 (c index = 0.799). Model 4 had a high predictive value (c index 0.848, P = 0.013). Decision curve analysis confirmed that biological behaviour represented the best prognostic parameter. Conclusion: This study presented some limitations: single centre, retrospective design and a long period of enrolment. The result showed that, by increasing the cut-off of the G2 category to 5% or by creating two subgroups in the G2 category, it was possible to obtain a better stratification of patients. (C) 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 50 条
  • [41] Ki-67 index of 5% could better predict the clinical prognosis of well-differentiated pancreatic neuroendocrine tumours
    Yuan, Bing
    Shi, Yanfen
    Li, Yuanliang
    Tan, Haidong
    Jiao, Peipei
    Su, Wenting
    Liu, Meng
    Qi, Zhirong
    Tan, Huangying
    Luo, Jie
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1708 - 1714
  • [42] Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases
    Heymann, MF
    Joubert, M
    Nemeth, J
    Franc, B
    Visset, J
    Hamy, A
    le Borgne, J
    le Neel, JC
    Murat, A
    Cordel, S
    le Bodic, MF
    HISTOPATHOLOGY, 2000, 36 (05) : 421 - 432
  • [43] The Treatment of Pancreatic Neuroendocrine Tumors - A Retrospective Single-Centre Study
    Gavrilescu, Mihaela-Madalina
    Hutanu, Ionut
    Scripcariu, Dragos Viorel
    Filip, Bogdan
    Anitei, Maria-Gabriela
    Radu, Iulian
    Scripcariu, Viorel
    CHIRURGIA, 2025, 120 (01)
  • [44] Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases
    Singhi, Aatur D.
    Klimstra, David S.
    HISTOPATHOLOGY, 2018, 72 (01) : 168 - 177
  • [45] mTOR Activation in Well Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Study on 34 Cases
    Zhou, Chen-Fei
    Ji, Jun
    Yuan, Fei
    Shi, Min
    Zhang, Jun
    Liu, Bing-Ya
    Zhu, Zheng-Gang
    HEPATO-GASTROENTEROLOGY, 2011, 58 (112) : 2140 - 2143
  • [46] PHASE II STUDY OF SUNITINIB (SU) IN JAPANESE PATIENTS WITH WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMOR (NET)
    Igarashi, H.
    Okusaka, T.
    Ito, T.
    Nishida, T.
    Hashigaki, S.
    Kimura, N.
    Ohki, E.
    Sawaki, A.
    Yamao, K.
    Imamura, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [47] Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors
    Wang, Hebin
    Ding, Ding
    Qin, Tingting
    Zhang, Hang
    Liu, Jun
    Zhao, Junfang
    Wu, Chien-Hui
    Javed, Ammar
    Wolfgang, Christopher
    Guo, Shiwei
    Chen, Qingmin
    Zhao, Weihong
    Shi, Wei
    Zhu, Feng
    Guo, Xingjun
    Li, Xu
    Peng, Feng
    He, Ruizhi
    Xu, Simiao
    Jin, Jikuan
    Wu, Yi
    Nuer, Abula
    Edil, Barish
    Tien, Yu-Wen
    Jin, Gang
    Zheng, Lei
    He, Jin
    Liu, Jianhua
    Liu, Yahui
    Wang, Min
    Qin, Renyi
    HPB, 2022, 24 (05) : 681 - 690
  • [48] Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
    Ito, Tetsuhide
    Okusaka, Takuji
    Nishida, Toshirou
    Yamao, Kenji
    Igarashi, Hisato
    Morizane, Chigusa
    Kondo, Shunsuke
    Mizuno, Nobumasa
    Hara, Kazuo
    Sawaki, Akira
    Hashigaki, Satoshi
    Kimura, Nobuyuki
    Murakami, Mami
    Ohki, Emiko
    Chao, Richard C.
    Imamura, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1265 - 1274
  • [49] Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
    Tetsuhide Ito
    Takuji Okusaka
    Toshirou Nishida
    Kenji Yamao
    Hisato Igarashi
    Chigusa Morizane
    Shunsuke Kondo
    Nobumasa Mizuno
    Kazuo Hara
    Akira Sawaki
    Satoshi Hashigaki
    Nobuyuki Kimura
    Mami Murakami
    Emiko Ohki
    Richard C. Chao
    Masayuki Imamura
    Investigational New Drugs, 2013, 31 : 1265 - 1274
  • [50] 177Lu-DOTATATE in patients with well-differentiated neuroendocrine tumors and skeletal metastases: A single-centre experience
    Satapathy, S.
    Ballal, S.
    Yadav, M. P.
    Sahoo, R. K.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S665 - S665